Table 2.
Univariate analyses for PFS and OS in ICIs monotherapy group and all patients
| ICIs mono‐therapy | All patients | |||||||
|---|---|---|---|---|---|---|---|---|
| Factors | Median PFS (month) | P‐value | Median OS (month) | P‐value | Median PFS (month) | P‐value | Median OS (month) | P‐value |
| Age (<65 vs. ≥65) | 5.3 vs. 6.7 | 0.516 | 23.5 vs. 20.1 | 0.859 | 8.6 vs. 9.6 | 0.767 | 23.9 vs. 20.1 | 0.864 |
| Gender (male vs. female) | 5.9 vs. 3.6 | 0.589 | 22.5 vs. NR | 0.462 | 9.2 vs. 5.8 | 0.344 | 23.5 vs. NR | 0.691 |
| Smoking history (never/light vs. heavy) | 5.3 vs. 5.9 | 0.702 | 23.9 vs. 22.5 | 0.516 | 8.6 vs. 8.8 | 0.720 | 24.6 vs. 23.5 | 0.271 |
| Pathology (squamous vs. nonsquamous NSCLC) | 4.8 vs. 6.3 | 0.905 | 12.9 vs. 23.9 | 0.037 | 5.9 vs. 9.8 | 0.187 | 15.7 vs. 23.9 | 0.056 |
| Bone metastasis (No vs. Yes) | 6.7 vs. 4.2 | 0.048 | 23.9 vs. 12.5 | 0.004 | 9.2 vs. 8.6 | 0.376 | 23.9 vs. 17.6 | 0.158 |
| Other organ metastasis (No vs. Yes) | 4.4 vs. 5.9 | 0.843 | 22.5 vs. 23.8 | 0.785 | 7.4 vs. 8.8 | 0.738 | 23.5 vs 23.8 | 0.331 |
| ECOG performance status (0–1 vs. ≥2) | 5.9 vs. 2.3 | 0.261 | 22.5 vs. 7.8 | 0.049 | 8.8 vs. 3.2 | 0.127 | 23.8 vs. 7.8 | 0.001 |
| Treatment line (1 vs. ≥2) | 11.8 vs. 4.8 | 0.212 | 23.5 vs. 22.5 | 0.504 | 11.4 vs. 5.9 | 0.011 | NR vs 22.5 | 0.031 |
| Treatment (ICI monotherapy vs. combined therapy) | — | — | — | — | 5.9 vs. 11.4 | 0.026 | 22.5 vs. 24.6 | 0.147 |